Shire Provides Results For Phase 3b Vyvanse Study

Shire has announced the results of Phase 3b study of Vyvanse (lisdexamfetamine dimesylate) CII that showed significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD).

Vyvanse is currently approved by the FDA for the treatment of ADHD in children age 6 to 12 years and in adults with ADHD.

The study supports the results of a previous phase 3 clinical trial in adults in which once-daily Vyvanse significantly improved ADHD symptoms of inattention, such as the ability to focus and organize, as well as hyperactivity and impulsivity.

Michael Yasick, Senior Vice President of ADHD Business Unit at Shire, said: This study provides important information for physicians about the effect of treatment with VYVANSE throughout the day in adults.

“We are proud to have evaluated VYVANSE in adults in this workplace-like environment.”